GLP-1 Weight Loss Medications in New York

New York has stricter telehealth licensing than most states. The state does not participate in the Interstate Medical Licensure Compact, meaning out-of-state physicians must register with the NYS Education Department before providing telehealth to New York patients. This limits the pool of available telehealth providers compared to compact member states. However, major national telehealth platforms have registered providers in New York, so access is not significantly impaired for patients using established services.

New York enacted legislation in 2024 requiring commercial health insurers to cover FDA-approved anti-obesity medications, including GLP-1 receptor agonists prescribed for weight management. This was a landmark change that significantly improved access for state-regulated plans. Insurers may still impose prior authorization, step therapy, and quantity limits, but cannot exclude the medication class entirely. Note that self-funded employer plans (ERISA plans), which are common among NYC-based employers, are not subject to this state mandate.

New York City has among the highest concentration of obesity medicine specialists in the country, with programs at NYU Langone, Mount Sinai, Columbia, and Weill Cornell. Upstate New York has far fewer in-person options, with specialists concentrated in Albany, Rochester, Syracuse, and Buffalo. Telehealth bridges this gap effectively, giving upstate residents access to the same providers and medication options as NYC patients.

The New York State Board of Pharmacy regulates compounding under strict standards. In-state 503A pharmacies can compound patient-specific prescriptions, and 503B outsourcing facilities can ship into New York. New York has been scrutinizing compounding practices more closely as GLP-1 demand has surged. Patients should verify their compounding pharmacy is properly licensed and follows USP 797 sterile compounding standards.